SAN FRANCISCO, CA--(Marketwired - March 31, 2014) - Medivation, Inc. (NASDAQ: MDVN) today announced the appointment of Rick Bierly as chief financial officer, effective March 31, 2014. Rick will serve as Medivation's principal financial and accounting officer and will report to David Hung, M.D., president and chief executive officer.
As previously announced, after more than 10 years as Medivation's chief business and financial officer, Patrick Machado is retiring from his position.
"Pat's contributions to our success have been invaluable as we've grown from a small start up into a commercial organization with a product approved in over 35 countries around the world. We are extremely fortunate to have his help as Medivation transitions to a new CFO," said David Hung, M.D., president and chief executive officer of Medivation. "Rick brings many years of deep and varied financial expertise in the Life Sciences industry and will be an asset to Medivation as we continue to grow our business to capture new opportunities. On behalf of the board and the other members of the executive team, it is a pleasure to welcome Rick to Medivation."
Rick Bierly added, "This is an exciting time to be joining Medivation as the company looks to expand its XTANDI® (enzalutamide) franchise and invest in new programs in areas of unmet medical need. I look forward to working closely with the Medivation team to achieve the organization's growth goals."
Rick Bierly brings to Medivation over 30 years' experience in finance roles at Glaxo-SmithKline, Aventis, Centocor and Johnson & Johnson. Among these roles were biotechnology CFO, diagnostics CFO, Treasurer, External Reporting director, head of shared services and operational finance roles in support of sales, marketing, supply chain and R&D. He began his career in public accounting at Ernst & Young (EY), and most recently served as an executive director in EY's Financial Accounting Advisory Services practice. Rick holds a Bachelor of Business Administration degree from Pennsylvania State University and is a CPA in PA and NJ.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com.